Compare Nutrien Ltd (NTR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Viatris Inc — how do they compare? Nutrien Ltd trades at $67.48 (market cap $33.31B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Viatris Inc for 57 Days on average.
| NTR | VTRS | |
|---|---|---|
Market Cap | $33.31B | $20.03B |
Volume | 1,330,729 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $18.27 |
52-Week Low | $53.64 | $9.74 |
Typical Hold Time | 59 Days | 57 Days |
Enterprise Value | $45.11B | $32.15B |
Dividend Yield | 3.15% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.87, down 0.14% with a bearish technical signal despite positive analyst sentiment. The company shows improving fundamentals with 2025 revenue of $26.89B and net income of $2.27B, representing an 8.44% margin. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates. Cash flow trends indicate operational strength with $4.01B from operations in 2025, though net cash flow remains negative. The stock faces headwinds from fertilizer industry challenges but benefits from strong potash demand and cost discipline.
NTR presents a moderate buy opportunity with 60.61% analyst buy ratings and $76.14 consensus price target offering 9% upside. Key catalysts include November 2026 Investor Day and structural gas arbitrage benefits, while risks involve fertilizer price volatility, geopolitical supply disruptions, and sulfur cost pressures. The company's North American nitrogen assets provide competitive advantage, but investors should monitor agricultural cycle trends and input cost management.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
